{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:17:50Z","timestamp":1694639870646},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.ejim.2010.03.015","type":"journal-article","created":{"date-parts":[[2010,5,14]],"date-time":"2010-05-14T08:40:34Z","timestamp":1273826434000},"page":"293-296","source":"Crossref","is-referenced-by-count":10,"title":["The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients"],"prefix":"10.1016","volume":"21","author":[{"given":"L.E.","family":"Degreef","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.L.","family":"Opdam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.M.","family":"Teepe-Twiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Jukema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.J.","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.T.","family":"Tamsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2010.03.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HJR.0b013e32831215db","article-title":"Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol","volume":"16","author":"Corsini","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ejim.2010.03.015_bib2","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"issue":"Suppl 2","key":"10.1016\/j.ejim.2010.03.015_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/01.hjr.0000277983.23934.c9","volume":"14","author":"Graham","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"issue":"14","key":"10.1016\/j.ejim.2010.03.015_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.ejim.2010.03.015_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.ejim.2010.03.015_bib6","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2010.03.015_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2010.03.015_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1074248406288758","article-title":"Statin-induced myopathy: the two faces of Janus","volume":"11","author":"Arora","year":"2006","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ejim.2010.03.015_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/BOR.0b013e328010c559","article-title":"Myotoxicity associated with lipid-lowering drugs","volume":"19","author":"Baer","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.ejim.2010.03.015_bib10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"issue":"11","key":"10.1016\/j.ejim.2010.03.015_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2010.03.015_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2010.03.015_bib13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.ejim.2010.03.015_bib14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0002-8703(02)00140-0","article-title":"Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS)","volume":"144","author":"Matalka","year":"2002","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.ejim.2010.03.015_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00592-006-0216-4","article-title":"Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia","volume":"43","author":"Ferrer-Garcia","year":"2006","journal-title":"Acta Diabetol"},{"issue":"12","key":"10.1016\/j.ejim.2010.03.015_bib16","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5mg and 10mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2010.03.015_bib17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5 to 20mg) in patients with a previous statin intolerance","volume":"103","author":"Ruisinger","year":"2009","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2010.03.015_bib18","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.amjcard.2007.03.059","article-title":"Effects of once weekly rosuvastatin among patients with a prior statin intolerance","volume":"100","author":"Backes","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ejim.2010.03.015_bib19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.amjcard.2006.07.093","article-title":"Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy","volume":"99","author":"Mackie","year":"2007","journal-title":"Am J Cardiol"},{"issue":"8513","key":"10.1016\/j.ejim.2010.03.015_bib20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(86)90598-2","article-title":"Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia","volume":"2","author":"Mol","year":"1986","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2010.03.015_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy \u2014 a genowide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620510000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T19:49:57Z","timestamp":1635364197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620510000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0953620510000580"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2010.03.015","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}